Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Johnson & Johnson (

Aaron Rodgers oddly called Travis Kelce ‘Mr. Pfizer’ despite playing for the Johnson & Johnson heir

Aaron Rodgers can be such a dork, man.

USA Today Sports Media Group

In rare interview, J&J CEO Joaquin Duato opens up about Baby Powder cancer lawsuits and the future of Kenvue

J&J CEO Joaquin Duato's interview on Baby Powder cancer lawsuits, Kenvue, and the COVID vaccine.

Fortune

Johnson & Johnson Stock Looks Like Good Value Now

Johnson & Johnson stock (JNJ) recently spun off its consumer Kenvue business, which trades separately under the symbol KVUE. However, JNJ stock has dipped and now looks like good value.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Protect Your Returns With These 3 Dividend Kings!

Looking for long-term income and stability? Here's 3 dividend kings you won't want to miss!

Barchart

Protect Your Returns With These Three Dividend Kings!

Looking for long-term income and stability? Here's 3 dividend kings you won't want to miss!

Barchart

Lawyers lose in better deal for pelvic mesh victims

A law firm that ran two class actions for women harmed by pelvic mesh implants will lose out on a $38.5 million cut of $405 million in settlement funds.

AAP

This J&J exec sold Tylenol and Listerine. Now she runs its $27B medtech business

Ashley McEvoy pivoted from over-the-counter products to medical devices.

Fortune

Read news from The Economist, FT, and more,
with one subscription

Johnson & Johnson is getting rid of its script logo after more than 130 years

Johnson & Johnson is signing off on a new logo, more than 130 years after creating the old one

The Independent UK

Cricketer Harmanpreet Kaur on TIME100 NEXT 2023 list of emerging leaders

NEW DELHI: Three notable Indians, including cricketer Harmanpreet Kaur, have earned a spot on TIME magazine's prestigious "2023 TIME100 Next: the Emerging Leaders Shaping the World" list. The list also featured Nandita Venkatesan and Vinu Daniel. It also featured Indian-origin Nabarun Dasgupta.

The Times of India

Fake Sudafed Is Bullshit, Just As You Suspected

Legal restrictions on pseudoephedrine have not reduced meth use, but they have driven people with colds or allergies toward substitutes that seem to be completely ineffective.

Reason

A popular nasal decongestant doesn't actually relieve congestion, FDA advisers say

The FDA asked advisers to take another look at phenylephrine, which became the main drug in over-the-counter decongestants when medicines with an older ingredient were moved behind pharmacy counters.

WEKU

Popular nasal decongestant ingredient doesn’t relieve congestion, FDA advisers say

Advisers to the Food and Drug Administration voted unanimously on Tuesday against the effectiveness of the key drug phenylephrine found in popular versions of Sudafed, Dayquil and other medications stocked on store shelves.

Chicago Sun-Times

Popular nasal decongestant doesn't actually relieve congestion, FDA experts say

Government advisers say the leading decongestant used by millions of Americans to treat nasal congestion doesn't actually work

The Independent UK

Unusual Options Activity in Johnson & Johnson Post Its Kenvue Spinoff Highlights Its Value

An unusual number of out-of-the-money put options in Johnson & Johnson come after the Aug. 30 spinoff of its consumer Kenvue business. This could be a good income play for short-put traders.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Salon

About the new drug pricing negotiations

The first eligible drugs treat diabetes, blood clots, blood cancers, arthritis and heart disease

Chicago Sun-Times

5 things consumers need to know about Medicare’s new drug-pricing negotiations, how they’ll affect you

This could help people whose Medicare drug plans require big copayments. But the main relief will come from part of the Inflation Reduction Act that caps drug spending by Medicare recipients at $2,000 a year starting in 2025.

The Guardian - UK

Cost of tuberculosis treatment halved in deal to permit generic versions

Johnson & Johnson’s year-long deal on life-saving drug bedaquiline is seen as critical move in campaign against disease

StockNews.com

Is Johnson & Johnson (JNJ) a Buy Before September Begins?

Pharma giant Johnson & Johnson (JNJ) has posted robust second-quarter results and raised its full-year outlook. Should investors look into the stock before September begins? Let’s look at its financial metrics to gauge its prospects….

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Kenvue Joins S&P 500 on Friday: Time to Buy?

S&P Dow Jones Indices announced on Monday that Kenvue would join the S&P 500 on Friday. Tuesday’s volume and rising share price suggest that investors feel now is the time to buy its stock.

Reason

'Private Tyranny' Is Less Private Than You Think

Sohrab Ahmari inadvertently gives even more reasons to reduce the power of the state.

The Independent UK

Newly released FBI tapes show suspect suggesting how Tylenol murders were carried out

In the 2008 footage James Lewis is seen going into detail about how the Tylenol killer would have carried out the poisonings

StockNews.com

Is Johnson & Johnson (JNJ) a Must-Buy Stability Stock?

Thanks to the company’s solid first-quarter performance and growing pharmaceutical demand, Johnson & Johnson’s (JNJ) long-term prospects look bright. However, could the company ensure stability for investors amid the current market volatility? Keep reading….

Fortune

Newest Fortune 500 member says large companies lose focus: 'You are little more remote from where the action is'

Kenvue, spun off from Johnson & Johnson in May, generated $15 billion in sales last year, enough to put it at rank 275 on 2022's Fortune 500 list.

The Hindu

MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India

MSF reiterated its call for Johnson & Johnson to publicly announce that it will not enforce any ‘secondary’ patents for bedaquiline in any country with a high burden of TB, as J&J’s 20-year primary patent on bedaquiline expired on July 18.

The Guardian - UK

Cheaper TB drugs for millions after global deal on patent rights agreed

Johnson & Johnson allows generic bedaquiline in 44 countries – but concerns remain about ‘stopgap’ solution

1 … 10 11 12 13

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

212 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.